Evidence map›Paper›PMID 36432614›Full record

ArticleNutrients2022

Association of α-Dicarbonyls and Advanced Glycation End Products with Insulin Resistance in Non-Diabetic Young Subjects: A Case-Control Study.

Melinda Csongová, Jean L J M Scheijen, Marjo P H van de Waarenburg, Radana Gurecká, Ivana Koborová, Tamás Tábi, Éva Szökö, Casper G Schalkwijk, Katarína Šebeková

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Dietary Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic Complications.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Review
  3. Observational
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Receptor for the Advanced Glycation End Products (International journal of molecular sciences · 2023
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Melinda CsongováInstitute of Molecular Biomedicine, Medical Faculty, Comenius University, 811 07 Bratislava, Slovakia.
Jean L J M ScheijenDepartment of Internal Medicine, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands.
Marjo P H van de WaarenburgDepartment of Internal Medicine, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands.
Radana GureckáInstitute of Molecular Biomedicine, Medical Faculty, Comenius University, 811 07 Bratislava, Slovakia.ORCID 0000-0002-5880-666X
Ivana KoborováInstitute of Molecular Biomedicine, Medical Faculty, Comenius University, 811 07 Bratislava, Slovakia.
Tamás TábiDepartment of Pharmacodynamics, Faculty of Pharmacy, Semmelweis University, 1089 Budapest, Hungary.ORCID 0000-0001-5343-0205
Éva SzököDepartment of Pharmacodynamics, Faculty of Pharmacy, Semmelweis University, 1089 Budapest, Hungary.
Casper G SchalkwijkDepartment of Internal Medicine, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands.
Katarína ŠebekováInstitute of Molecular Biomedicine, Medical Faculty, Comenius University, 811 07 Bratislava, Slovakia.ORCID 0000-0002-9641-9265
Comenius University Bratislava · SKMaastricht University Medical Centre · NLSemmelweis University · HU

Funding

Association for Regional Cooperation in the Fields of Health, Science and Technology (RECOOP HST Association) to I.K.Bratislava Self-governing Region not numberedEuropean Association for the Study of Diabetes to M.C.International Visegrad Fund 51400162Slovak Research and Development Agency 0447-12
6 · The paper itself

Abstract

α-Dicarbonyls and advanced glycation end products (AGEs) may contribute to the pathogenesis of insulin resistance by a variety of mechanisms. To investigate whether young insulin-resistant subjects present markers of increased dicarbonyl stress, we determined serum α-dicarbonyls-methylglyoxal, glyoxal, 3-deoxyglucosone; their derived free- and protein-bound, and urinary AGEs using the UPLC/MS-MS method; soluble receptors for AGEs (sRAGE), and cardiometabolic risk markers in 142 (49% females) insulin resistant (Quantitative Insulin Sensitivity Check Index (QUICKI) ≤ 0.319) and 167 (47% females) age-, and waist-to-height ratio-matched insulin-sensitive controls aged 16-to-22 years. The between-group comparison was performed using the two-factor (sex, presence/absence of insulin resistance) analysis of variance; multiple regression via the orthogonal projection to latent structures model. In comparison with their insulin-sensitive peers, young healthy insulin-resistant individuals without diabetes manifest alterations throughout the α-dicarbonyls-AGEs-sRAGE axis, dominated by higher 3-deoxyglucosone levels. Variables of α-dicarbonyls-AGEs-sRAGE axis were associated with insulin sensitivity independently from cardiometabolic risk markers, and sex-specifically. Cleaved RAGE associates with QUICKI only in males; while multiple α-dicarbonyls and AGEs independently associate with QUICKI particularly in females, who displayed a more advantageous cardiometabolic profile compared with males. Further studies are needed to elucidate whether interventions alleviating dicarbonyl stress ameliorate insulin resistance.

Indexed as

Cardiovascular DiseasesInsulin ResistanceCase-Control StudiesFemaleGlycation End Products, AdvancedHumansInsulinMaleGlycation End Products, AdvancedInsulinadvanced glycation end productscardiometabolic riskD-lactateinsulin resistancesex differencessRAGEsVAP-1α-dicarbonyls

Identifiers

PMID36432614
PMCPMC9695161
OpenAlexW4309720293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.